Development of Agonist-Based PROTACs Targeting Liver X Receptor

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Liver X receptors (LXRs) are nuclear receptors regulating lipid and cholesterol metabolism.
• LXR antagonists show potential for treating hypercholesterolemia and diabetes.
• Current LXR inhibitors are limited, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To develop LXR degraders using proteolysis targeting chimeras (PROTACs) as a novel therapeutic approach.
• To investigate the efficacy of PROTACs in degrading LXR proteins.
• To establish a complementary strategy to LXR inhibition.

Main Methods:

• Design and synthesis of a PROTAC molecule targeting LXRβ (GW3965-PEG5-VH032).
• Assessment of LXRβ protein degradation.
• Investigation of the involvement of the ubiquitin-proteasome system and VHL E3 ligase.

Main Results:

• Successful development of a PROTAC (compound 3) capable of degrading LXRβ protein.
• Demonstration of ubiquitin-proteasome system-dependent degradation of LXRβ.
• Confirmation of VHL E3 ligase requirement for degradation.

Conclusions:

• PROTACs targeting LXR proteins represent a viable complementary strategy to LXR inhibition.
• The developed PROTAC effectively degrades LXRβ protein.
• Targeting LXRs with PROTACs holds potential for novel therapeutic agents in LXR-related diseases.